Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor ...
Q2 2026
Aug 6, 2026
Q1 2026
Apr 30, 2026
FY 2025
Mar 9, 2026
Q4 2025
Q3 2025
Nov 6, 2025